Quantcast

Latest Desmopressin Stories

2014-08-26 08:30:42

- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions - MISSISSAUGA, ON, Aug. 26, 2014 /CNW/ - Today Biogen Idec (NASDAQ: BIIB) announces that Health Canada has approved ELOCTATE(TM) [Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein] for the control and prevention of bleeding episodes and routine prophylaxis in adults and children aged 12 and older with hemophilia A.(1) ELOCTATE is...

2014-07-10 08:28:53

LOS ANGELES, July 10, 2014 /PRNewswire/ -- Sleep Apnea Doctors US aims to help doctors find patients in their local area through an innovative method: the online search engine. With this tool, patients across the nation have easier access to care and can finally see relief from disruptive sleep apnea symptoms like insomnia. Listing with Sleep Apnea Doctors US as a sleep apnea doctor is as easy as creating a social media account. Doctors are even able to sign in online using their...

2014-06-13 16:23:29

LOS ANGELES, June 13, 2014 /PRNewswire/ -- Sleep Apnea Doctors US is now looking to assist doctors in finding local sleep apnea patients through a complimentary listing on the site. Sleep disorders such as sleep apnea are extremely common. According to the National Institute of Neurological Disorders and Stroke, an estimated 40 million Americans suffer from chronic sleep disorders, and 20 million have occasional sleep problems. These sleep disorders can have negative far-reaching...

2014-05-12 08:31:01

- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults...

2014-04-17 08:28:45

- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/ -- Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a...

2014-04-17 08:22:44

Inspirational video is launched on World Hemophilia Day to tell the story of one Canadian's triumph over adversity TORONTO, April 17, 2014 /CNW/ - Attitude makes you a hero; that's why John Schmitke, Vice President and Chairman of the Youth Committee at the Canadian Hemophilia Society, Manitoba Chapter, is working to empower and inspire those with hemophilia by sharing his own positive approach to living with this blood disorder. On World Hemophilia Day (April 17, 2014), John...

2014-04-16 08:32:37

6.9 million people have a bleeding disorder. 75 percent of them don't know it. MONTREAL, April 16, 2014 /PRNewswire/ -- Every year on April 17, World Hemophilia Day is observed around the world to increase awareness of hemophilia and other inherited bleeding disorders. In 2014, World Hemophilia Day's theme will encourage the younger generation of the global bleeding disorders community to "Speak out. Create change." "World Hemophilia Day is part of our critical effort to aid in...

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related